- Home
- MIY vs TNGX Comparison
MIY vs TNGX Comparison
Compare MIY & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- TNGX
- Stock Information
- Founded
- MIY 1992
- TNGX 2014
- Country
- MIY United States
- TNGX United States
- Employees
- MIY N/A
- TNGX N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MIY Finance
- TNGX Health Care
- Exchange
- MIY Nasdaq
- TNGX Nasdaq
- Market Cap
- MIY 318.9M
- TNGX 351.2M
- IPO Year
- MIY N/A
- TNGX N/A
- Fundamental
- Price
- MIY $11.03
- TNGX $6.10
- Analyst Decision
- MIY
- TNGX Strong Buy
- Analyst Count
- MIY 0
- TNGX 6
- Target Price
- MIY N/A
- TNGX $12.20
- AVG Volume (30 Days)
- MIY 56.8K
- TNGX 2.9M
- Earning Date
- MIY 01-01-0001
- TNGX 08-06-2025
- Dividend Yield
- MIY 3.98%
- TNGX N/A
- EPS Growth
- MIY N/A
- TNGX N/A
- EPS
- MIY N/A
- TNGX N/A
- Revenue
- MIY N/A
- TNGX $40,990,000.00
- Revenue This Year
- MIY N/A
- TNGX N/A
- Revenue Next Year
- MIY N/A
- TNGX N/A
- P/E Ratio
- MIY N/A
- TNGX N/A
- Revenue Growth
- MIY N/A
- TNGX 10.09
- 52 Week Low
- MIY $9.45
- TNGX $1.03
- 52 Week High
- MIY $11.70
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MIY 42.28
- TNGX 74.27
- Support Level
- MIY $11.00
- TNGX $5.34
- Resistance Level
- MIY $11.08
- TNGX $5.63
- Average True Range (ATR)
- MIY 0.08
- TNGX 0.50
- MACD
- MIY 0.01
- TNGX -0.04
- Stochastic Oscillator
- MIY 69.10
- TNGX 84.15
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.